185 related articles for article (PubMed ID: 29453769)
61. Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.
Chan KKL; Liu SS; Wei N; Ngu SF; Chu MMY; Tse KY; Lau LSK; Cheung ANY; Ngan HYS
Int J Cancer; 2020 Aug; 147(4):1152-1162. PubMed ID: 31922265
[TBL] [Abstract][Full Text] [Related]
62. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
[TBL] [Abstract][Full Text] [Related]
63. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
[TBL] [Abstract][Full Text] [Related]
64. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
[TBL] [Abstract][Full Text] [Related]
65. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
[TBL] [Abstract][Full Text] [Related]
66. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
[TBL] [Abstract][Full Text] [Related]
67. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
68. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer.
Hesselink AT; Berkhof J; Heideman DA; Bulkmans NW; van Tellingen JE; Meijer CJ; Snijders PJ
Int J Cancer; 2009 Jan; 124(2):381-6. PubMed ID: 19003961
[TBL] [Abstract][Full Text] [Related]
69. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
70. Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.
Guerrero-Preston R; Valle BL; Jedlicka A; Turaga N; Folawiyo O; Pirini F; Lawson F; Vergura A; Noordhuis M; Dziedzic A; Pérez G; Renehan M; Guerrero-Diaz C; De Jesus Rodríguez E; Diaz-Montes T; Rodríguez Orengo J; Méndez K; Romaguera J; Trock BJ; Florea L; Sidransky D
Cancer Prev Res (Phila); 2016 Dec; 9(12):915-924. PubMed ID: 27671338
[TBL] [Abstract][Full Text] [Related]
71. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
[TBL] [Abstract][Full Text] [Related]
72. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
[TBL] [Abstract][Full Text] [Related]
74. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grades 1 or worse among 4215 Chinese women in a population-based study.
Zhang R; Velicer C; Chen W; Liaw KL; Wu EQ; Liu B; Cui JF; Belinson JL; Zhang X; Shen GH; Chen F; Qiao YL
Cancer Epidemiol; 2013 Dec; 37(6):939-45. PubMed ID: 24210584
[TBL] [Abstract][Full Text] [Related]
75. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
76. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
77. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
78. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
80. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
